Bruker Further Enhances Clinical Microbiology & Infection Diagnostics Portfolio at ESCMID Global 2024 Conference
26 Abril 2024 - 6:00AM
Business Wire
- New MBT Pathfinder® IVD robot for automated MALDI Biotyper®
target preparation
- New LiquidArray® MTB-XDR panel for simultaneous detection of
M. tuberculosis complex bacteria, and their resistances to five
WHO-recommended second-line drugs against multidrug-resistant
tuberculosis
- Pending ELITech acquisition has received all regulatory
clearances; closing now expected in the second quarter of
2024
At the ESCMID Global 2024 conference, Bruker is enhancing its
innovative diagnostic solutions in microbial identification,
antimicrobial susceptibility testing (AST), early sepsis
diagnostics, and other infectious disease assays. Simplifying
microbiology and infectious disease diagnostics and workflows in
the clinical laboratory is a key goal for Bruker in support of
earlier and improved patient treatment decisions.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20240426543414/en/
MBT Pathfinder® IVD with Feeder IVD
(Photo: Business Wire)
Microbial identification – towards automated sample
preparation
The latest MALDI Biotyper® workflow uses MBT Compass HT IVD
software to increase throughput up to 600 samples per hour, and
automated instrument tuning via IDealTune™. An optional workflow
now offers semi-automated sample preparation via the MBT
Pathfinder® IVD robot to avoid time-consuming, repetitive and
error-prone manual tasks.
Sepsis – when every minute counts
When the correct antibiotic treatment for sepsis is given
quickly, outcomes can improve dramatically. The IVD-CE MALDI
Biotyper®, used in conjunction with the MBT Sepsityper® IVD Kit,
can identify pathogens within 20 minutes from a positive blood
culture bottle. Bruker offers additional clinical workflows for
rapid functional antibiotic resistance testing, like the MBT
STAR®-Carba IVD assay for the detection of carbapenemase
activity.
Antimicrobial susceptibility testing (AST)
AST can indicate which antimicrobial regimen is effective for
patients. Bruker’s UMIC® tests deliver accurate results for single
antibiotics and combinations, and the MICRONAUT range offers AST of
multiple antibiotics in a single test in a user-friendly workflow
in compliance with CLSI/EUCAST recommendations. The UMIC® portfolio
covers five antibiotics and combinations, namely colistin,
piperacillin-tazobactam, vancomycin/teicoplanin, daptomycin and
cefiderocol.
In addition, Bruker is developing the new MBT-fAST assay for
rapid AST of gram-negative bacteria from positive blood cultures
directly on the MALDI Biotyper® platform. The MBT-fAST clinical
studies are planned for the second half of 2024.
Bruker also intends concurrent clinical studies for IVDR
certification of lipid A-based colistin resistance detection. This
and the on-going development of microbial species and subspecies
differentiation based on lipid patterns will further enhance the
value of the MALDI Biotyper® sirius system for clinical
laboratories. The MALDI Biotyper® sirius stands out as the first
MALDI-TOF mass spectrometry system for microbial identification
that uses the negative ion mode for microbial lipid analysis.
Currently, this feature is for Research Use Only (RUO), setting the
stage for forthcoming clinical applications.
Outbreak control
The Bruker IR Biotyper® enables efficient microbial strain
typing of bacteria and yeasts for real-time epidemiological
surveillance for a range of disease-causing pathogens. During
outbreak scenarios within hospitals, the IR Biotyper can help
prevent the spread of hospital-acquired infections (HAI). The IR
Biotyper® for hospital hygiene and infection control can be
combined with the MALDI Biotyper® for microbial species
identification.
LiquidArray® – next-generation syndromic panels
The new LiquidArray® Gastrointestinal syndromic panel
facilitates the simultaneous detection of up to 26 pathogens
responsible for gastroenteritis. This streamlines clinical
decision-making by allowing the simultaneous analysis of multiple
targets from a single sample.
The rise of multidrug-resistant and extensively drug resistant
M. tuberculosis strains has added complexity to TB diagnosis and
treatment – and global travel is causing re-emergence in formerly
low risk countries. Bruker’s new multiplex mycobacteria test
LiquidArray® MTB-XDR VER 1.0, detects TB-causing bacteria of the M.
tuberculosis complex and identifies resistance to five
WHO-recommended second-line drugs.
Dr. Wolfgang Pusch, President of the Bruker Microbiology &
Infection Diagnostics division, commented: “Bruker is committed to
innovation in routine microbiology and infectious disease testing.
This includes nearly universal microbial identification with the
MALDI Biotyper®, rapid blood culture analysis with the MBT
Sepsityper® IVD Kit, early implementation of diagnostics for new
antibiotics with our UMIC® portfolio, real-time epidemiological
surveillance with the IR Biotyper®, and syndromic panels with our
LiquidArray® assay portfolio.”
Pending ELITechGroup Acquisition Regulatory
Clearances
As announced on February 28, 2024, Bruker Corporation has signed
a Share Purchase Agreement to acquire ELITechGroup, excluding the
ELITech clinical chemistry business. All regulatory clearances for
this acquisition have now been received, and closing of the
acquisition is expected during Q2 2024, subject to remaining
closing conditions.
About Bruker Corporation – Leader of the Post-Genomic Era
(Nasdaq: BRKR)
Bruker is enabling scientists and engineers to make breakthrough
post-genomic discoveries and develop new applications that improve
the quality of human life. Bruker’s high performance scientific
instruments and high value analytical and diagnostic solutions
enable scientists to explore life and materials at molecular,
cellular, and microscopic levels. In close cooperation with our
customers, Bruker is enabling innovation, improved productivity,
and customer success in post-genomic life science molecular and
cell biology research, in applied and biopharma applications, in
microscopy and nanoanalysis, as well as in industrial and cleantech
research, and next-gen semiconductor metrology in support of AI.
Bruker offers differentiated, high-value life science and
diagnostics systems and solutions in preclinical imaging, clinical
phenomics research, proteomics and multiomics, spatial and
single-cell biology, functional structural and condensate biology,
as well as in clinical microbiology and molecular diagnostics. For
more information, please visit www.bruker.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240426543414/en/
Trade Press & Customer Contact: Philip Perry Senior
Vice President, Marketing and Product Management Bruker
Microbiology & Infection Diagnostics Division T:
+49-172-313-7216 E: philip.perry@bruker.com
Investor Contact: Justin Ward Sr. Director, Investor
Relations & Corporate Development Bruker Corporation T: +1
(978) 313-5800 E: Investor.Relations@bruker.com
Bruker (NASDAQ:BRKR)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Bruker (NASDAQ:BRKR)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024